Protective effect of Shengmai injection on myocardial endothelial cell glycoprotein detachment after myocardial ischemia-reperfusion injury in isolated rat hearts

Chen, Qi; Zhang, Ping; Xiao, Qiu‐Xia; Liu, Qing; Zhang, Ying

doi:10.1177/0267659120965921

Cited by 7 publications

(4 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is often used to treat chronic obstructive pulmonary disease [ 77 ], diabetic myocardium disease [ 78 ], and coronary atherosclerotic heart disease [ 79 ]. It exerts its action primarily by improving mitochondrial lipid metabolism and inhibiting oxidative stress damage [ 80 ]. Research on ginseng has mainly focused on saponins, polysaccharides, and volatile components.…”

Section: The ‘Three Syndromes and Six Chinese Patent Medicines’ Projectmentioning

confidence: 99%

The three syndromes and six Chinese patent medicine study during the recovery phase of COVID-19

Duan

Zhang

et al. 2021

Chin Med

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), first broke out in Wuhan, China, in 2019. SARS-CoV-2 develops many types of mutations (such as B.1.1.7), making diagnosis and treatment challenging. Although we now have a preliminary understanding of COVID-19, including pathological changes, clinical manifestations, and treatment measures, we also face new difficulties. The biggest problem is that most COVID-19 patients might face sequelae (e.g., fatigue, sleep disturbance, pulmonary fibrosis) during the recovery phase. We aimed to test six Chinese patent medicines to treat three major abnormal symptoms in COVID-19 patients during the recovery phase, including cardiopulmonary function, sleep disturbance, and digestive function. We launched the “three syndromes and six Chinese patent medicines” randomized, double-blind, placebo-controlled, multicenter clinical trial on April 10, 2020. The results showed that Jinshuibao tablets and Shengmaiyin oral liquid significantly improved the cardiopulmonary function of recovering COVID-19 patients. Shumian capsules, but not Xiaoyao capsules, significantly improved patients’ sleep disorders. This might be because the indication of Xiaoyao capsules is liver qi stagnation rather than psychological or emotional problems. Xiangsha Liujun pills and Ludangshen oral liquid significantly improved digestive function. Our research provides a guideline for treating COVID-19 sequelae in patients during the recovery period based on high-quality evidence.

show abstract

Section: The ‘Three Syndromes and Six Chinese Patent Medicines’ Projectmentioning

confidence: 99%

The three syndromes and six Chinese patent medicine study during the recovery phase of COVID-19

Duan

Zhang

et al. 2021

Chin Med

View full text Add to dashboard Cite

show abstract

“…O. falcata is used in Tibetan Medicine to treat several diseases, including leprosy, rheumatic pain, back pain, influenza, and tonsillitis [ 47 ]. Several anti-MIRI drugs have been developed from plant-derived natural compounds in recent years, exhibiting multiple pharmacological activities [ 60 , 61 , 62 ]. In addition, our previous studies found that the extracts of O. falcata have a protective effect on MIRI, although the specific mechanism was not clear [ 23 , 31 , 33 ].…”

Section: Discussionmentioning

confidence: 99%

Mechanism of Action of Flavonoids of Oxytropis falcata on the Alleviation of Myocardial Ischemia–Reperfusion Injury

et al. 2022

View full text Add to dashboard Cite

Oxytropis falcata Bunge is a plant used in traditional Tibetan medicine, with reported anti-inflammatory and antioxidants effects and alleviation of myocardial ischemia reperfusion injury (MIRI). However, the underlying mechanism against MIRI and the phytochemical composition of O. falcata are vague. One fraction named OFF1 with anti-MIRI activity was obtained from O. falcata, and the chemical constituents were identified by ultra-high-performance liquid chromatography coupled with tandem mass spectrometry (UHPLC–MS). The potential targets and signaling pathways involved in the action of O. falcata against MIRI were predicted by network pharmacology analysis, and its molecular mechanism on MIRI was determined by in vitro assays. The results revealed that flavonoids are the dominant constituents of OFF1. A total of 92 flavonoids reported in O. falcata targeted 213 potential MIRI-associated factors, including tumor necrosis factor (TNF), prostaglandin-endoperoxide synthase 2 (PTGS2), and the NF-κB signaling pathway. The in vitro assay on H9c2 cardiomyocytes subjected to hypoxia/reoxygenation injury confirmed that the flavonoids in OFF1 reduced myocardial marker levels, apoptotic rate, and the inflammatory response triggered by oxidative stress. Moreover, OFF1 attenuated MIRI by downregulating the ROS-mediated JNK/p38MAPK/NF-κB pathway. Collectively, these findings provide novel insights into the molecular mechanism of O. falcata in alleviating MIRI, being a potential therapeutic candidate.

show abstract

“…In this study, we found that SMY had the same effect as Met in improving cardiac function damage, which led us to believe that SMY can protect the heart from diabetes. SMY, a traditional Chinese medicine, is commonly used in the clinic to treat cardiac insufficiency, coronary heart disease, and heart failure [ 8 , 9 , 30 ]. SMY could restore the cardiac function of CHF rats, reduce serum biochemical indexes, reduce cardiac tissue damage, and reduce the expression levels of ALOX15 and CYP1A2, which may be related to the linoleic acid metabolic pathway [ 10 ].…”

Section: Discussionmentioning

confidence: 99%

“…Sheng Mai Yin (SMY) is composed of ginseng, radix ophiopogonis, and Schisandra chinensis. Some studies have shown that the Sheng Mai compound preparation composed of three Chinese herbs has therapeutic efects on heart diseases such as myocardial ischemia-reperfusion, coronary heart disease, and heart failure [8][9][10]. By activating AMPKα and decreasing oxidative stress injury mediated by NADPH oxidase, Sheng Mai San (SMS) has been reported to protect the myocardium against diabetes [11].…”

Section: Introductionmentioning

confidence: 99%

The Protective Effect of Sheng Mai Yin on Diabetic Cardiomyopathy via NLRP3/Caspase-1 Pathway

Zhao

Peng

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Sheng Mai Yin (SMY) has therapeutic effects on myocardial infarction (MI), heart failure (HF), diabetic cardiomyopathy (DCM), and myocarditis. To study whether SMY can relieve pyroptosis and play a protective role in diabetic cardiomyopathy, a molecular docking technique was used to predict the possible mechanism of SMY against DCM. Then, a DCM rat model was induced by intraperitoneal injection of streptozotocin (STZ), divided into 5 groups: the DM group (model), SMY-L group (2.7 mL/kg SMY), SMY-M group (5.4 mL/kg SMY), SMY-H group (10.8 mL/kg SMY), and Met group (120 mg/kg metformin). Rats in the CTL group (control) and DM group were given normal saline. After 8 weeks, the levels of blood glucose, lipids, and myocardial enzymes were detected according to the kit instructions. Cardiac function was detected by echocardiography. HE and Masson were used to observing the pathological changes, collagen deposition, and collagen volume fraction (CVF). The apoptosis rate of cardiomyocytes was determined by Tunel. The IL-1β level was determined by ELISA and RT-PCR. The expressions of NLRP3, caspase-1, and GSDMD were measured using RT-PCR and Western blotting. The docking results suggested that SMY may act on NLRP3 and its downstream signal pathway. The in vivo results showed that SMY could reduce blood glucose and lipid levels, improve heart function, improve histopathological changes and myocardial enzymes, and alleviate cardiomyocyte apoptosis and myocardial fibrosis. SMY inhibited the mRNA and protein expressions of NLRP3, ASC, Caspase-1, and GSDMD and IL-1β production. SMY can reduce DCM by regulating the NLRP3/caspase-1 signaling pathway, providing a new research direction for the treatment of DCM.

show abstract

Protective effect of Shengmai injection on myocardial endothelial cell glycoprotein detachment after myocardial ischemia-reperfusion injury in isolated rat hearts

Cited by 7 publications

References 43 publications

The three syndromes and six Chinese patent medicine study during the recovery phase of COVID-19

The three syndromes and six Chinese patent medicine study during the recovery phase of COVID-19

Mechanism of Action of Flavonoids of Oxytropis falcata on the Alleviation of Myocardial Ischemia–Reperfusion Injury

The Protective Effect of Sheng Mai Yin on Diabetic Cardiomyopathy via NLRP3/Caspase-1 Pathway

Contact Info

Product

Resources

About